Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

MegaNatural BP® GSE on Blood Pressure and Cardiometabolic Risk Factors

NCT06555952 · View on ClinicalTrials.gov ↗

Study Summary

Inflammation and stressors can interfere with the function of the lining of blood vessels and insulin activity, therefore, investigators are aiming to see how the Grape seed Extract (GSE) called MegaNatural BP can help with limiting the effects of these factors. This research will study the effects of taking 150mg of MegaNatural BP GSE per day on blood pressure levels along with influences on heart health through assessing the function of the blood vessel lining and levels of inflammation.

Interventions

  • OTHER Placebo Capsule
  • DIETARY_SUPPLEMENT MegaNatural-BP SR 150Mg Tablet

Study Locations (1)

Illinois

  • Clinical Nutrition Research Center — Chicago

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2024-08-08
Est. Completion 2026-12-31
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06555952

The ClinicalTrials.gov registry entry for NCT06555952 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clinical Nutrition Research Center, Illinois Institute of Technology, which has 15 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions — of which Placebo Capsule is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06555952 reports 1 study location spanning 1 distinct geographic area — top geographies include Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06555952 about?

NCT06555952 is a clinical study titled "MegaNatural BP® GSE on Blood Pressure and Cardiometabolic Risk Factors". Inflammation and stressors can interfere with the function of the lining of blood vessels and insulin activity, therefore, investigators are aiming to see how the Grape seed Extract (GSE) called MegaNatural BP can help with limiting the effects of these factors. This research will study the effects ...

What is the current status of trial NCT06555952?

This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2024-08-08. Estimated completion is 2026-12-31.

What conditions does trial NCT06555952 study?

This clinical trial studies the following conditions: Hypertension, Pre Diabetes. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06555952?

The interventions under investigation include: Placebo Capsule (OTHER), MegaNatural-BP SR 150Mg Tablet (DIETARY_SUPPLEMENT). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06555952?

This trial is sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology, which has 15 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06555952 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial